Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
April 11, 2019 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
March 18, 2019 17:31 ET
|
Scholar Rock
Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage CompanyPresented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy...
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
March 12, 2019 16:30 ET
|
Scholar Rock
Selective inhibition of TGFβ1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism of primary resistance...
Scholar Rock to Participate in Upcoming Investor Conferences
March 06, 2019 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in...
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
February 26, 2019 07:00 ET
|
Scholar Rock
Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA)Pharmacodynamic Results Demonstrate Robust and Sustained Target...
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 08:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
December 03, 2018 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
November 29, 2018 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
November 27, 2018 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
November 19, 2018 16:05 ET
|
Scholar Rock
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...